ProfileGDS4814 / ILMN_1762714
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 37% 34% 8% 21% 7% 8% 1% 41% 42% 22% 19% 22% 57% 44% 14% 19% 27% 40% 8% 40% 22% 20% 44% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)47.05437
GSM780708Untreated after 4 days (C2_1)46.386634
GSM780709Untreated after 4 days (C3_1)40.67548
GSM780719Untreated after 4 days (C1_2)43.752921
GSM780720Untreated after 4 days (C2_2)40.14667
GSM780721Untreated after 4 days (C3_2)40.63158
GSM780710Trastuzumab treated after 4 days (T1_1)33.24271
GSM780711Trastuzumab treated after 4 days (T2_1)47.927241
GSM780712Trastuzumab treated after 4 days (T3_1)48.160642
GSM780722Trastuzumab treated after 4 days (T1_2)44.049122
GSM780723Trastuzumab treated after 4 days (T2_2)43.324919
GSM780724Trastuzumab treated after 4 days (T3_2)44.062222
GSM780713Pertuzumab treated after 4 days (P1_1)53.601557
GSM780714Pertuzumab treated after 4 days (P2_1)48.767244
GSM780715Pertuzumab treated after 4 days (P3_1)42.135914
GSM780725Pertuzumab treated after 4 days (P1_2)43.409319
GSM780726Pertuzumab treated after 4 days (P2_2)44.988127
GSM780727Pertuzumab treated after 4 days (P3_2)47.848140
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)40.67458
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)47.760840
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)44.016722
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)43.546620
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)48.637644